



HAL
open science

Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate-or High-Risk RET Mutations Do Not Predict Disease Aggressiveness"

Frederic Castinetti, Nelson Whollk

► **To cite this version:**

Frederic Castinetti, Nelson Whollk. Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate-or High-Risk RET Mutations Do Not Predict Disease Aggressiveness". *Journal of Clinical Endocrinology and Metabolism*, 2017, 102 (8), pp.2807 - 2813. 10.1210/jc.2017-00317 . hal-01724172

HAL Id: hal-01724172

<https://amu.hal.science/hal-01724172>

Submitted on 10 Apr 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the Editor: “Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk *RET* Mutations Do Not Predict Disease Aggressiveness”

Frederic Castinetti¹ and Nelson Whollk²

¹Aix Marseille University, CNRS UMR7286, Assistance Publique Hopitaux de Marseille, La Conception Hospital, Marseille, France; and ²Endocrine Section, Universidad de Chile, Hospital del Salvador, Santiago de Chile, Chile

We thank Voss *et al.* (1) for their interesting study about the overall outcome of patients with moderate- and high-risk multiple endocrine neoplasia type 2, American Thyroid Association classification A (MEN2A). The authors compared the mortality and time to distant metastases in patients carrying moderate- and high-risk (634 codon) mutations of *RET*, and they did not observe any significant difference. They recommend modifying the schematic of the American Thyroid Association classification by replacing moderate and high risk with “late” and “early disease onset.” This is of importance as it is the first time that the idea of parallel survival curves is suggested, the only difference being the time of disease onset. We would like to share two main concerns about this study, and the reasons why we think this new terminology might be premature.

First, in retrospective studies, the mortality is always biased by the management of the patients. Given the fact that the authors initially considered 634 *RET* mutations as high risk, it would be interesting to know whether their management was different between both groups: number of cervical surgeries, radiotherapy, targeted therapy, or chemotherapy. A more aggressive management in patients carrying 634 *RET* mutations would lead to a better outcome, but would also be an evidence in favor of a more aggressive disease. The authors also elegantly showed that the time to the first distant metastasis was comparable; however, isolated slow-growing metastasis does not behave like multiple fast-growing metastases, and this information would also be of importance to better characterize the outcome of the disease, particularly in view of the different age at last follow-up between both groups. Indeed, in the results, it is stated that the median age at diagnosis was 42 and 23 years

and the median follow-up time was 6.5 and 11.5 years for moderate- and high-risk groups, respectively. Thus, one-half of the patients with 634 *RET* mutations were censored by age 34.5 vs 48.5 in the moderate-risk group. A longer follow-up is undoubtedly necessary to ascertain that the mortality would be identical at the same final age.

Second, endocrinologists dealing with MEN2A have always noticed the wide phenotypic variability among patients (age at distant metastasis, final outcome). The authors recently reported that a worst outcome or progression differed among 12 families with the same *RET* mutation; they “recommended counseling patients with codon 634 mutations that their MTC [medullary thyroid carcinoma] disease course cannot be predicted by that of their relatives” (2). This emphasizes the difficulty in predicting the outcome of such patients as a whole. The term “risk” is thus a reminder for the clinicians that MEN2A should lead to appropriate treatment as soon as possible. Replacing the term risk by onset would likely tone down the dramatic outcome of some of the patients carrying 634 *RET* mutations. In the absence of larger-scale studies (as recommended by the authors in their discussion) with long-term follow-up that would confirm the interesting data shown in this study, we thus think that a semantic replacement is premature and would send a wrong message to the clinicians dealing with MEN2A.

Acknowledgments

Address all correspondence and requests for reprints to: Frederic Castinetti, MD, PhD, Department of Endocrinology,

Abbreviation: MEN2, multiple endocrine neoplasia type 2, American Thyroid Association classification A.

La Conception Hospital, 147 Boulevard Baille, 13005 Marseille, France. E-mail: Frederic.castinetti@ap-hm.fr.

Disclosure Summary: The authors have nothing to disclose.

References

1. Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk *RET* mutations do not predict disease aggressiveness [published online ahead of print May 9, 2017]. *J Clin Endocrinol Metab*. doi:10.1210/jc.2017-00317.
2. Long KL, Etzel C, Rich T, Hyde S, Perrier ND, Graham PH, Lee JE, Hu MI, Cote GJ, Gagel R, Grubbs EG. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. *Fam Cancer*. 2017;**16**(2):283–289.